MALARIA ERADICATION
THROUGH VACCINATION
Sanaria's vaccines are intended to be used to prevent malaria in individuals and, in combination with other malaria control measures, to halt transmission of and eliminate malaria from communities.
Sanaria is a proud sponsor of Frontiers in Science and Medicine Day 2011
Watch the great video!
Initial Trial Of Sanaria’s Malaria Vaccine Yields Positive Results
Positive results from the initial Phase 1 clinical trial in 80 healthy volunteers and complementary pre-clinical studies of the Sanaria® PfSPZ Vaccine are published today in the online issue of Science (www.sciencexpress.org).
Sanaria announces the launch of its Sanaria® Family of Products and Services
Sanaria announces the launch of its Sanaria® Family of Products and Services intended to advance research towards new malaria vaccines, drugs, and diagnostics, and enhanced understanding of malaria pathology and immunobiology.
Peter F. Billingsley PhD, Senior Director of Entomology and Quality Systems, joins Editorial Board of the Malaria Journal
Dr. Billingsley joins a distinguished group of malariologists, in recognition of more than 20 years experience in medical entomology and malaria research. Peter has previously served on the editorial boards of major parasitology and entomology journals, the College of Experts for the Medical Research Council (UK), and advisory boards for mosquito control trials in Africa.
The Quest for a Malaria Vaccine and the Man Who Risked Everything to Find It
Dr. Stephen Hoffman learned about malaria the hard way—by rolling up his sleeves and letting thousands of infected mosquitoes bite him. Back in mid-1990s, Stephen Hoffman dipped his arm into a swarm of malaria-infected mosquitoes. But he didn’t expect to get sick. At the time, he thought he’d invented a vaccine that would keep him disease free. He was wrong. Read the full article in Mental Floss!
Sanaria honored to be ranked 15th among all Maryland businesses in The Gazette of Politics and Business Exceptional 53 Business Awards
Check out the full list of winners at The Gazette.
An Urgent Need for Malaria Vaccines
Sanaria has an innovative approach to malaria vaccines using Plasmodium falciparum (Pf) sporozoites (SPZ) as the platform technology for immunizing people against malaria infection. The proven effective results of this approach are documented in Sanaria’s publications.
Global Collaboration: The I-PfSPZ Consortium
Semi-annually, Sanaria organizes the international PfSPZ Consortium (i-PfSPZ-C) meeting for our partners, collaborators and funders where we analyze, present and discuss our findings prior to publication. The i-PfSPZ-C allows our collaborators and partners to share their work, modify research and clinical plans based on the consortium efforts and map out future funding needs.
Subscribe
Our Malaria Vaccine Pipeline
Innovative routes to success. A major impact in global health.